Sequenom Announces Launch of SensiGene Fetal(XY) - Fetal Sex Determination Test
News Feb 17, 2010
Sequenom, Inc. has announced the launch of the SensiGene™ Fetal(XY) (Fetal Sex Determination) test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's second laboratory developed test powered by its SEQureDx™ technology.
According to the Company, benefits of the SensiGene Fetal(XY) Fetal Sex Determination test include:
• Noninvasive and safe. The test requires only a simple blood sample from the mother.
• Early detection - first trimester fetal sex determination.
• Highly specific - allows the distinction between maternal and fetal DNA for both male and female fetuses.
"The launch of the SensiGene Fetal(XY) test represents another successful noninvasive prenatal test demonstrating the utility of using maternal blood to determine fetal status," said Lee P. Shulman, MD, Professor of Obstetrics and Gynecology and Chief of the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University.
He continued, "This is a great leap forward in delivering a test with a high degree of accuracy, using cutting-edge technology which has been rigorously evaluated through blinded studies, performed in collaboration with internationally recognized prenatal diagnosticians. This test adds to the physicians' prenatal diagnostic arsenal by providing for safe and accurate noninvasive fetal testing."
Tweak to Technique Could Bolster Disease DetectionNews
A team of Stanford researchers has developed a technique that they hope could more precisely detect diseases or disorders such as cancer or a heart attack.READ MORE
Immune Cells That Keep Gut Fungi Under Control IdentifiedNews
Immune cells that process food and bacterial antigens in the intestines control the intestinal population of fungi, according to a new study from Weill Cornell Medicine scientists.READ MORE
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE